Top

International Urogynecology Journal

Published in:

01-09-2018 | Review Article

Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis

Authors: Giampiero Capobianco, Antonio Azzena, Laura Saderi, Francesco Dessole, Salvatore Dessole, Giovanni Sotgiu

Published in: International Urogynecology Journal | Issue 9/2018

Abstract

Introduction and hypothesis

The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI).

Methods

A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018.

Results

Eight full texts were evaluated but only five were selected for the qualitative and quantitative analyses. Duration of follow-up after Urolastic® injections was significantly heterogeneous, ranging from 6 to 24 months. Secondary injections were needed in 16.7%–35.0% of the treated patients. The pooled proportion of secondary injections was 20% (95% CI: 15%–24%; I²: 0%). Subjective improvement, measured by different means (i.e., patient global impression of improvement PGI-I score) was only assessed by 40% of the selected papers and was > 80% in two cohorts. The objective treatment success was evaluated by four (80.0%) papers and was achieved in all cohorts with a wide proportional range: from 32.7% (i.e., patients without objective SUI symptom cough tests and with a negative pad test) to 67.0%. Its pooled proportion was 57% (95% CI: 38%–75%; I²: 82.3%).

Conclusions

Urolastic® showed effectiveness in patients with SUI during a follow-up period of 6–24 months.

Tantanasis T, Daniilidis A, Pantelis A, Chatzis P, Vrachnis N. Minimally invasive techniques for female stress urinary incontinence, how, why. when Arch Gynecol Obstet. 2013;288(5):995–1001.CrossRefPubMed

Hunskaar S, Burgio K, Diokno A, Herzog AR, Hjälmås K, Lapitan MC. Epidemiology and natural history of urinary incontinence in women. Urology. 2003;62(4 Suppl 1):16–23.CrossRefPubMed

Patel DA, Xu X, Thomason AD, Ransom SB, Ivy JS, DeLancey JO. Childbirth and pelvic floor dysfunction: an epidemiologic approach to the assessment of prevention opportunities at delivery. Am J Obstet Gynecol. 2006;195(1):23–8.CrossRefPubMedPubMedCentral

Alas AN, Chinthakanan O, Espaillat L, Plowright L, Davila GW, Aguilar VC. De novo stress urinary incontinence after pelvic organ prolapse surgery in women without occult incontinence. Int Urogynecol J. 2017;28(4):583–90.CrossRefPubMed

Capobianco G, Wenger JM, Meloni GB, Dessole M, Cherchi PL, Dessole S. Triple therapy with lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2014;289(3):601–8.CrossRefPubMed

Dumoulin C, Hay-Smith EJ, Mac Habee-Seguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2014;(5):CD005654.

Urinary Incontinence in Women: the Management of Urinary Incontinence in Women: NICE Clinical Guideline CG171, National Institute for Health and Care Excellence, London (UK), 2013 Available: http://guidance.nice.org.uk/CG171.

Capobianco G, Madonia M, Morelli S, Dessole F, De Vita D, Cherchi PL, Dessole S. Management of female stress urinary incontinence: a care pathway and update. Maturitas 2018; 109: 32–38.

Kurien A, Narang S, Han HC. Tension-free vaginal tape-Abbrevo procedure for female stress urinary incontinence: a prospective analysis over 22 months. Singap Med J. 2017;58(6):338–42.CrossRef

10.

Capobianco G, Dessole M, Lutzoni R, Surico D, Ambrosini G, Dessole S. TVT-ABBREVO: efficacy and two years follow-up for the treatment of stress urinary incontinence. Clin Exp Obstet Gynecol. 2014;41(4):445–7.PubMed

11.

American Urological Association. Incontinence 2017. https://www.auanet.org/education/guidelines/incontinence.cfm.

12.

Mamut A, Carlson KV. Periurethral bulking agents for female stress urinary incontinence in Canada. Can Urol Assoc J. 2017 Jun;11(6 Suppl 2):S152–4.CrossRefPubMedPubMedCentral

13.

Herschorn S. Injection therapy for urinary incontinence. In: Wein A, Kavoussi LR, Novick AC, et al., editors. Campbell-Walsh urology. 11th ed. Philadelphia: Saunders; 2013. p. 2049–69.

14.

Kotb AF, Campeau L, Corcos J. Urethral bulking agents: techniques and outcomes. Curr Urol Rep. 2009;10:396–400.CrossRefPubMed

15.

Kowalik CR, Casteleijn FM, van Eijndhoven HWF, Zwolsman SE, Roovers JWR. Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery. Neurourol Urodyn 2018;37(1):339–345.

16.

Renard J, Citeri M, Zanollo L, Guerrer C, Rizzato L, Frediani L, et al. Treatment of stress urinary incontinence in neurological patients with an injectable elastomer prosthesis: preliminary results. Int Neurourol J. 2017;21(1):75–9.CrossRefPubMedPubMedCentral

17.

de Vries AM, van Breda HMK, Fernandes JG, Venema PL, Heesakkers JPFA. Para-urethral injections with Urolastic® for treatment of female stress urinary incontinence: subjective improvement and safety. Urol Int. 2017;99(1):91–7.CrossRefPubMedPubMedCentral

18.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.CrossRefPubMed

19.

Zajda J, Farag F. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up. Cent European J Urol. 2015;68(3):334–8.PubMedPubMedCentral

20.

Futyma K, Miotła P, Gałczyński K, Baranowski W, Doniec J, Wodzisławska A, et al. An open multicenter study of clinical efficacy and safety of Urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. Biomed Res Int. 2015;2015:851823.CrossRefPubMedPubMedCentral

21.

Futyma K, Nowakowski Ł, Gałczyński K, Miotła P, Rechberger T. Nonabsorbable urethral bulking agent—clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. Eur J Obstet Gynecol Reprod Biol. 2016;207:68–72.CrossRefPubMed

22.

Zajda J, Farag F. Urolastic-a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. Adv Urol 2013. 2013;724082:1–5.

23.

Chan WKW, Chu PSK. Bulking agents in the management of urinary incontinence: dead or alive? Curr Bladder Dysfunct Rep. 2017;12(3):195–200.CrossRef

24.

Kasi AD, Pergialiotis V, Perrea DN, Khunda A, Doumouchtsis SK. Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature. Int Urogynecol J. 2016;27(3):367–75.CrossRefPubMed

25.

Siddiqui ZA, Abboudi H, Crawford R, Shah S. Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review. Int Urogynecol J. 2017;28(29):1275–84.CrossRefPubMed

26.

Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183(4):1444–9.CrossRefPubMed

27.

Kirchin V, Page T, Keegan PE, Atiemo K, Cody JD, McClinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2012;(2): CD003881.

Title: Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis
Authors: Giampiero Capobianco
Antonio Azzena
Laura Saderi
Francesco Dessole
Salvatore Dessole
Giovanni Sotgiu
Publication date: 01-09-2018
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 9/2018
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-018-3703-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2018

Method and reliability of measuring midurethral area and echogenicity, and changes during and after pregnancy

Autologous rectus fascia sling placement in the management of female stress urinary incontinence

The urethral closure mechanism is deteriorated after anterior colporrhaphy

A randomized comparison of a single-incision needleless (Contasure-needleless®) mini-sling versus an inside-out transobturator (Contasure-KIM®) mid-urethral sling in women with stress urinary incontinence: 24-month follow-up results

The impact of fellowship surgical training on operative time and patient morbidity during robotics-assisted sacrocolpopexy

Readmission and reoperation after midurethral sling